video interview17 Oct 2013 10:29
e-Therapeutics has funds to take flagship cancer drug to a possible licencing deal
Daniel Elger, CFO of e-Therapeutics (LON:ETX), tells Proactiveinvestors that the company is making good progress with its flagship ETS2101 treatment for brain cancers with a near doubling of patients in Phase I trials. Daniel also announces that the cash ETX has, will now cover R&D into 2018 and, as a result, subject to favourable trials, on to a licencing deal.
http://tinyurl.com/nbszk5r